|
|
Immuno Chemistry Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 |
|
Request for Sample Pages |
| Published Date : 16 January 2012 |
|
|
|
Pages : 248 |
|
| |
|
|
|
|
|
|
|
Immuno Chemistry Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
Summary
Company’s new report, Immuno Chemistry Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 provides key market data on the Immuno Chemistry market in the BRICS countries. The report provides value ($m) data for each segment and sub-segment within nine market categories – Disease Specific Immunochemistry, Endocrinology Tests, Immunochemistry Rapid Tests, Immunochemistry Analyzers, Organ Function Assays, Anemia / Vitamin Tests, Therapeutic Drug Monitoring, Specific Proteins and Drugs of Abuse / Toxicology. The report also provides company shares and distribution shares data for the overall Immuno Chemistry market in each of the aforementioned countries. The report is also supplemented with global corporate-level profiles of the key market participants with information on key developments, wherever available.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.
The emerging economies, comprising China, India, Brazil, Russia and South Africa, with a significantly large pool of under-served patients, represent the next big opportunity for the leading medical equipment and devices manufacturers. China remains the world’s most populous country and is consequently home to a large patient base. The country is home to more than 120 million people who are aged 65 or older—a population in continuous need of medical care. India, the second most populous country globally, is home to 1.2 billion people, approximately 5% of which are aged 65 or older. It’s estimated that shortly after 2020, India’s population will surpass China, making it the most populous country in the world. As the population continues to grow and people continue to age, the underlying demand for healthcare is also expected to increase.
Scope
- Market size data for Immuno Chemistry market categories – Disease Specific Immunochemistry, Endocrinology Tests, Immunochemistry Rapid Tests, Immunochemistry Analyzers, Organ Function Assays, Anemia / Vitamin Tests, Therapeutic Drug Monitoring, Specific Proteins and Drugs of Abuse / Toxicology.
- Annualized market revenues ($m) data for each of the segments and sub-segments within the nine market categories. Data from 2003 to 2010, forecast forward for seven years to 2017.
- 2010 company shares and distribution shares data for the overall Immuno Chemistry market in each of the aforementioned countries.
- Global corporate-level profiles of key companies operating within the Immuno Chemistry market in BRICS.
- Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc., bioMerieux S.A., Phadia AB, Alere Inc., Bio-Rad Laboratories, Inc., Transasia Bio-Medicals Ltd. and DiaSorin S.p.A.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Immuno Chemistry competitive landscape in BRICS.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize. |
|
|
|
Table of Contents : |
1.2 List of Figures
Figure 1: Immuno Chemistry, BRICS, Overall Revenue ($m), 2003-2017 17
Figure 2: Immuno Chemistry, BRICS, Overall Revenue ($m), Historic, 2003-2010 19
Figure 3: Immuno Chemistry, BRICS, Overall Revenue ($m), Forecast, 2010-2017 21
Figure 4: Immuno Chemistry, BRICS, Company share (%), 2010 23
Figure 5: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, 2003-2017 25
Figure 6: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, Historic, 2003-2010 27
Figure 7: Immuno Chemistry, Brazil, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 29
Figure 8: Disease Specific Immunochemistry, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 31
Figure 9: Disease Specific Immunochemistry, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 33
Figure 10: Endocrinology Tests, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 35
Figure 11: Endocrinology Tests, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 37
Figure 12: Organ Function Assays, Brazil, Revenue ($m), Historic, 2003-2010 38
Figure 13: Organ Function Assays, Brazil, Revenue ($m), Forecast, 2010-2017 39
Figure 14: Therapeutic Drug Monitoring, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 40
Figure 15: Therapeutic Drug Monitoring, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 42
Figure 16: Immunochemistry Analyzers, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 44
Figure 17: Immunochemistry Analyzers, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 46
Figure 18: Specific Proteins, Brazil, Revenue ($m), Historic, 2003-2010 48
Figure 19: Specific Proteins, Brazil, Revenue ($m), Forecast, 2010-2017 49
Figure 20: Anemia / Vitamin Tests, Brazil, Revenue ($m), Historic, 2003-2010 50
Figure 21: Anemia / Vitamin Tests, Brazil, Revenue ($m), Forecast, 2010-2017 51
Figure 22: Immunochemistry Rapid Tests, Brazil, Revenue ($m), Historic, 2003-2010 52
Figure 23: Immunochemistry Rapid Tests, Brazil, Revenue ($m), Forecast, 2010-2017 53
Figure 24: Drugs of Abuse / Toxicology, Brazil, Revenue ($m) by Segment, Historic, 2003-2010 54
Figure 25: Drugs of Abuse / Toxicology, Brazil, Revenue ($m) by Segment, Forecast, 2010-2017 56
Figure 26: Immuno Chemistry, Brazil, Company share (%), 2010 59
Figure 27: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, 2003-2017 61
Figure 28: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, Historic, 2003-2010 63
Figure 29: Immuno Chemistry, Russian Federation, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 65
Figure 30: Immunochemistry Analyzers, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 67
Figure 31: Immunochemistry Analyzers, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 69
Figure 32: Endocrinology Tests, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 71
Figure 33: Endocrinology Tests, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 73
Figure 34: Disease Specific Immunochemistry, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 75
Figure 35: Disease Specific Immunochemistry, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 77
Figure 36: Organ Function Assays, Russian Federation, Revenue ($m), Historic, 2003-2010 79
Figure 37: Organ Function Assays, Russian Federation, Revenue ($m), Forecast, 2010-2017 80
Figure 38: Anemia / Vitamin Tests, Russian Federation, Revenue ($m), Historic, 2003-2010 81
Figure 39: Anemia / Vitamin Tests, Russian Federation, Revenue ($m), Forecast, 2010-2017 82
Figure 40: Specific Proteins, Russian Federation, Revenue ($m), Historic, 2003-2010 83
Figure 41: Specific Proteins, Russian Federation, Revenue ($m), Forecast, 2010-2017 84
Figure 42: Therapeutic Drug Monitoring, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 85
Figure 43: Therapeutic Drug Monitoring, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 87
Figure 44: Drugs of Abuse / Toxicology, Russian Federation, Revenue ($m) by Segment, Historic, 2003-2010 89
Figure 45: Drugs of Abuse / Toxicology, Russian Federation, Revenue ($m) by Segment, Forecast, 2010-2017 91
Figure 46: Immunochemistry Rapid Tests, Russian Federation, Revenue ($m), Historic, 2003-2010 93
Figure 47: Immunochemistry Rapid Tests, Russian Federation, Revenue ($m), Forecast, 2010-2017 94
Figure 48: Immuno Chemistry, Russian Federation, Company share (%), 2010 96
Figure 49: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, 2003-2017 98
Figure 50: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 100
Figure 51: Immuno Chemistry, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 102
Figure 52: Endocrinology Tests, India, Revenue ($m) by Segment, Historic, 2003-2010 104
Figure 53: Endocrinology Tests, India, Revenue ($m) by Segment, Forecast, 2010-2017 106
Figure 54: Immunochemistry Rapid Tests, India, Revenue ($m), Historic, 2003-2010 108
Figure 55: Immunochemistry Rapid Tests, India, Revenue ($m), Forecast, 2010-2017 109
Figure 56: Immunochemistry Analyzers, India, Revenue ($m) by Segment, Historic, 2003-2010 110
Figure 57: Immunochemistry Analyzers, India, Revenue ($m) by Segment, Forecast, 2010-2017 112
Figure 58: Disease Specific Immunochemistry, India, Revenue ($m) by Segment, Historic, 2003-2010 114
Figure 59: Disease Specific Immunochemistry, India, Revenue ($m) by Segment, Forecast, 2010-2017 116
Figure 60: Organ Function Assays, India, Revenue ($m), Historic, 2003-2010 118
Figure 61: Organ Function Assays, India, Revenue ($m), Forecast, 2010-2017 119
Figure 62: Anemia / Vitamin Tests, India, Revenue ($m), Historic, 2003-2010 120
Figure 63: Anemia / Vitamin Tests, India, Revenue ($m), Forecast, 2010-2017 121
Figure 64: Drugs of Abuse / Toxicology, India, Revenue ($m) by Segment, Historic, 2003-2010 122
Figure 65: Drugs of Abuse / Toxicology, India, Revenue ($m) by Segment, Forecast, 2010-2017 124
Figure 66: Specific Proteins, India, Revenue ($m), Historic, 2003-2010 126
Figure 67: Specific Proteins, India, Revenue ($m), Forecast, 2010-2017 127
Figure 68: Therapeutic Drug Monitoring, India, Revenue ($m) by Segment, Historic, 2003-2010 128
Figure 69: Therapeutic Drug Monitoring, India, Revenue ($m) by Segment, Forecast, 2010-2017 130
Figure 70: Immuno Chemistry, India, Company share (%), 2010 133
Figure 71: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, 2003-2017 135
Figure 72: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 137
Figure 73: Immuno Chemistry, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 139
Figure 74: Disease Specific Immunochemistry, China, Revenue ($m) by Segment, Historic, 2003-2010 141
Figure 75: Disease Specific Immunochemistry, China, Revenue ($m) by Segment, Forecast, 2010-2017 143
Figure 76: Immunochemistry Rapid Tests, China, Revenue ($m), Historic, 2003-2010 145
Figure 77: Immunochemistry Rapid Tests, China, Revenue ($m), Forecast, 2010-2017 146
Figure 78: Endocrinology Tests, China, Revenue ($m) by Segment, Historic, 2003-2010 147
Figure 79: Endocrinology Tests, China, Revenue ($m) by Segment, Forecast, 2010-2017 149
Figure 80: Immunochemistry Analyzers, China, Revenue ($m) by Segment, Historic, 2003-2010 151
Figure 81: Immunochemistry Analyzers, China, Revenue ($m) by Segment, Forecast, 2010-2017 153
Figure 82: Organ Function Assays, China, Revenue ($m), Historic, 2003-2010 155
Figure 83: Organ Function Assays, China, Revenue ($m), Forecast, 2010-2017 156
Figure 84: Anemia / Vitamin Tests, China, Revenue ($m), Historic, 2003-2010 157
Figure 85: Anemia / Vitamin Tests, China, Revenue ($m), Forecast, 2010-2017 158
Figure 86: Specific Proteins, China, Revenue ($m), Historic, 2003-2010 159
Figure 87: Specific Proteins, China, Revenue ($m), Forecast, 2010-2017 160
Figure 88: Therapeutic Drug Monitoring, China, Revenue ($m) by Segment, Historic, 2003-2010 161
Figure 89: Therapeutic Drug Monitoring, China, Revenue ($m) by Segment, Forecast, 2010-2017 163
Figure 90: Drugs of Abuse / Toxicology, China, Revenue ($m) by Segment, Historic, 2003-2010 165
Figure 91: Drugs of Abuse / Toxicology, China, Revenue ($m) by Segment, Forecast, 2010-2017 167
Figure 92: Immuno Chemistry, China, Company share (%), 2010 170
Figure 93: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, 2003-2017 172
Figure 94: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, Historic, 2003-2010 174
Figure 95: Immuno Chemistry, South Africa, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 176
Figure 96: Disease Specific Immunochemistry, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 178
Figure 97: Disease Specific Immunochemistry, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 180
Figure 98: Immunochemistry Analyzers, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 182
Figure 99: Immunochemistry Analyzers, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 184
Figure 100: Organ Function Assays, South Africa, Revenue ($m), Historic, 2003-2010 186
Figure 101: Organ Function Assays, South Africa, Revenue ($m), Forecast, 2010-2017 187
Figure 102: Endocrinology Tests, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 188
Figure 103: Endocrinology Tests, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 190
Figure 104: Immunochemistry Rapid Tests, South Africa, Revenue ($m), Historic, 2003-2010 192
Figure 105: Immunochemistry Rapid Tests, South Africa, Revenue ($m), Forecast, 2010-2017 193
Figure 106: Specific Proteins, South Africa, Revenue ($m), Historic, 2003-2010 194
Figure 107: Specific Proteins, South Africa, Revenue ($m), Forecast, 2010-2017 195
Figure 108: Therapeutic Drug Monitoring, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 196
Figure 109: Therapeutic Drug Monitoring, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 198
Figure 110: Anemia / Vitamin Tests, South Africa, Revenue ($m), Historic, 2003-2010 200
Figure 111: Anemia / Vitamin Tests, South Africa, Revenue ($m), Forecast, 2010-2017 201
Figure 112: Drugs of Abuse / Toxicology, South Africa, Revenue ($m) by Segment, Historic, 2003-2010 202
Figure 113: Drugs of Abuse / Toxicology, South Africa, Revenue ($m) by Segment, Forecast, 2010-2017 204
Figure 114: Immuno Chemistry, South Africa, Company share (%), 2010 207
Figure 115: Siemens Healthcare, Company Share (%), BRICS Immuno Chemistry Market, 2010 210
Figure 116: F. Hoffmann-La Roche Ltd., Company Share (%), BRICS Immuno Chemistry Market, 2010 212
Figure 117: Abbott Laboratories, Company Share (%), BRICS Immuno Chemistry Market, 2010 215
Figure 118: Ortho-Clinical Diagnostics Inc., Company Share (%), BRICS Immuno Chemistry Market, 2010 217
Figure 119: Beckman Coulter, Inc., Company Share (%), BRICS Immuno Chemistry Market, 2010 220
Figure 120: bioMerieux S.A., Company Share (%), BRICS Immuno Chemistry Market, 2010 223
Figure 121: Phadia AB, Company Share (%), BRICS Immuno Chemistry Market, 2010 226
Figure 122: Alere Inc., Company Share (%), BRICS Immuno Chemistry Market, 2010 229
Figure 123: Bio-Rad Laboratories, Inc., Company Share (%), BRICS Immuno Chemistry Market, 2010 232
Figure 124: DiaSorin S.p.A, Company Share (%), BRICS Immuno Chemistry Market, 2010 236
Companies Mentioned
Siemens Healthcare
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Ortho-Clinical Diagnostics Inc.
Beckman Coulter, Inc.
bioMerieux S.A.
Phadia AB
Alere Inc.
Bio-Rad Laboratories, Inc.
Transasia Bio-Medicals Ltd.
DiaSorin S.p.A
Danaher Corporation
PerkinElmer, Inc.
Trivitron Healthcare Pvt Ltd.
Span Diagnostics Ltd.
OLYMPUS CORPORATION |
|
|
|
Published By : GlobalData |
|
|
Category
Related Report:
Automotive,
Automobile,
Aerospace & Aviation,
Banking,
Consumer Goods,
Construction,
Chemicals,
Defense,
Diabetes,
Disease,
Drinks,
Energy,
Electronics,
Financial
,
Food & Drinks,
Glass,
Healthcare,
Insurance,
Information technology,
Investment,
Industrial Gases,
Industry Profile,
Medical,
Media,
Marketing,
Miscellaneous,
Metals & Mining,
Nuclear Energy,
Oil & Gas,
Power,
Real Estate,
Software,
Solar,
Transportation
|
|
|
|
